There have been new discoveries in the way that congenital myotonic dystrophy (CDM) is inherited.
Many of you have seen posts on social media about treatments they have received in other countries or heard about through friends, that include everything from dietary aids to gene therapy, and want to how you can assess the possible benefits and risks of these 'treatments.' In this complicated therapy environment, how can patients make decisions about whether an available treatment or therapy is safe and effective? How can you tell the quacks from the cures?
Important review articles on disease mechanisms of and therapy development for DM have recently been published.
The UK DM Patient Registry reports on disease burden for 556 patients with a confirmed diagnosis of DM1.
MDF shares an update on program project grants from the NINDS.